Abstract
Despite being successful, we need to overcome the limitations of CAR therapy with T cells so that this immunotherapy can treat more patients with reduced cost and increased biosafety. The implementation of this therapy with NK cells brings the possibility of an "Off the shelf" allogeneic therapy, ready and available for treating patients. In addition to NK cells intrinsically eliminating …